DEA Enforcement Defense: Hemp Brand Avoids Controlled Substance Scheduling

The Challenge

A Colorado-based hemp-derived cannabinoid company with $18M in annual wholesale revenue received a DEA Administrative Subpoena and Notice of Intent to pursue civil forfeiture of product inventory — approximately 80,000 units of delta-8 THC gummies and tinctures valued at $3.2M at cost.

The DEA's position: delta-8 THC, although derived from hemp-legal CBD through isomerization, was a "synthetic" cannabinoid not exempted by the 2018 Farm Bill and was therefore a Schedule I controlled substance under the Federal Analogue Act (FAA). The company's products, the agency argued, were contraband subject to forfeiture.

The client had fourteen days to respond to the administrative subpoena before inventory seizure proceedings could begin. Their general business attorney had no controlled-substances experience and referred the matter to Hoban Law Group.

Our Approach

Immediate Litigation Hold. Bob Hoban's first action was to place a litigation hold on all inventory and to contact the DEA's counsel of record, asserting that the client disputed the controlled substance classification and intended to contest forfeiture. This preserved the client's administrative rights and created a procedural record.

Legal Position Paper. Within 72 hours, the firm produced a 34-page legal position paper establishing three independent defenses: (1) the 2018 Farm Bill's definition of "hemp" encompasses all cannabinoids, isomers, and salts derived from legal hemp, and delta-8 THC produced via CBD isomerization qualifies; (2) the Federal Analogue Act requires "substantially similar" pharmacological effect to a Schedule I substance, and delta-8 THC's profile is materially distinct from delta-9 THC; (3) the DEA's own Interim Final Rule of 2020 (86 FR 2021) did not clearly exclude hemp-derived delta-8 THC.

DEA Negotiation. We requested a pre-enforcement conference with the DEA's Special Agent in Charge and the U.S. Attorney's Office for the District of Colorado. The conference provided an opportunity to present the legal position paper and the client's GMP compliance documentation, demonstrating that the company was operating within what it understood to be a lawful regulatory framework.

Congressional and Agency Outreach. In parallel, Hoban Law Group coordinated with the client's trade association to file an emergency comment to the DEA requesting clarification of the Interim Final Rule's scope — generating a record of industry-wide reliance on the Farm Bill hemp exemption.

The Outcome

The DEA closed its enforcement action against the client without proceeding to forfeiture. The agency issued a "no further action" administrative determination, citing the "genuine legal ambiguity" surrounding hemp-derived delta-8 THC and the pending rulemaking proceeding.

The $3.2M inventory was released. The client implemented a voluntary product testing and labeling protocol recommended by Hoban Law Group — including delta-9 THC concentration certification per batch — to reduce re-enforcement risk during the rulemaking period.

The legal position paper developed for this matter was later submitted, with client consent, as part of a broader industry coalition comment to the DEA and served as a foundation for the firm's ongoing delta-8 THC practice.